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Background: Hereditary triple-negative breast cancer patients have better recurrence-free survival than triple-
negative sporadic ones. High expression of some of the miRNAs is related to worse overall and disease-free survival
of triple-negative breast cancer patients. The attempt to associate expression level of some miRNA in triple-negative
hereditary and sporadic breast cancers to disease specific survival was performed in this study.
Material and methods: Study group was made of 18 triple-negative breast cancer patients harboring the BRCA1
gene mutations and 32 triple-negative sporadic breast cancer patients. Quantitative amount of mir-10b, mir-21,
mir-29a, mir-31, and mir-214 by real-time PCR was assessed. The disease-specific survival in relation of high and low
levels of some of the miRNAs was analyzed using Log-rank (Mantel-Cox) test.
Results: MiR-214 showed significantly higher expression level in sporadic tissues than in hereditary ones (p = 0.0005).
Triple-negative breast cancer patients with high level of miR-214 showed significantly worse disease-specific survival
than patients with low level (p = 0.0314).
Conclusions: Our finding suggests that miR-214 possibly could be used as a potential prognostic biomarker for
triple-negative breast cancer patients.
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Breast cancer is the most wide spread tumor among
women worldwide. In the year 2008 approximately 1.38
million new cases were diagnosed, and 458,400 females
died from this malignancy [1]. The majority of these tu-
mors are sporadic while five to 10% are hereditary, and
significant proportion of them is due to the inherited
mutations either in the BRCA1 or BRCA2 gene [2,3].
There is a strong correlation between the presence of
mutations in the BRCA1/2 gene and morphology of the
breast cancer. The triple-negative (TN) morphology of
breast tumor is found in the 57% of patients with the
BRCA1 gene mutations and 23% of patients with the
BRCA2 gene mutations [4]. TN breast cancers are referred* Correspondence: dagnija.kalniete@rsu.lv
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unless otherwise stated.to estrogen receptor (ER) negative, progesterone receptor
(PR) negative, and human epidermal growth factor recep-
tor (HER2) negative tumors and they have tendency to be
more aggressive than other subtypes [5,6]. TN breast can-
cer patients harboring the BRCA1 mutations at the time
of the diagnosis are younger, have smaller tumor size, and
have significantly better recurrence-free and disease-
specific survival than TN breast cancer patients with no
mutations in the BRCA1 gene [7-10].
MiRNAs are non-coding small RNA molecules that
have the ability to regulate gene expression post-
transcriptionally, and are involved in the cell differenti-
ation, growth, and apoptosis [11,12]. In tumors, miRNA
expression is changed, and there is a correlation between
the changed expression and clinical features of the dis-
ease [13,14]. MiRNAs can act either as tumor inducers
or tumor suppressors, and either are up-regulated or
down-regulated [15]. One of the most studied tumorl. This is an Open Access article distributed under the terms of the Creative
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different types of malignancies, including breast cancer,
is miR-21 [14,16,17]. By inhibiting the tumor suppressor
tropomyosin-1 gene (TPM1) and programmed cell death
gene-4 (PDCD4), it is directly involved in the growth,
proliferation, and invasion of the tumor cells [18,19].
Another target of miR-21 is phosphatase and tensin
homolog gene (PTEN) that is involved in the PI3K/Akt
pathway [20-22]. In glioblastoma cells, miR-21 targets genes
that are involved in the major cancer suppression pathways:
in p53 pathway (JMY, TOPORS, IGFBP3, TP53PP2, DAXX,
HNRPK, and TP73L), in TGF-β pathway (TGFFBR2/3,
BHPK2, and DAXX), in mitochondrial apoptotic pathway
(APAF1 and PPIF) [23]. In breast cancer, the up-regulation
of this miRNA is associated with later clinical stage, higher
proliferation index Ki-67, and poor prognosis for the pa-
tient [14,17]. Breast cancer patients with tumor size more
than two centimeters have significantly higher expression
of miR-21 compared to those with tumor size less than
two centimeters [24]. Another oncogenic miRNA which
over-expression is associated with breast cancer is miR-
10b. MiR-10b is involved in the Rhoc-Akt signaling path-
way; Rhoc-Akt pathway is suppressed by the repression of
HOXD10 thus promoting cancer cell invasion [25]. More-
over, breast cancer patients with tumor size greater than
two centimeters have higher miR-10b expression than
those with tumor size less than two centimeters [24]. In
ovary cancers, miR-214 is expressed differently between
the carriers of the BRCA1 gene mutations and non-
carriers; miR-214 is down-regulated in the patients with
mutations in the BRCA1 gene [26]. One of the targets that
miR-214 regulate is PTEN gene; in the EGFR mutated
non-small lung tumor cell lines up-regulated miR-214
through the PTEN/AKT pathway induces resistance to ge-
fitinib [27].
Some of the miRNAs have shown different expressions
not only within the specific subtype of breast cancer but
among distinct subtypes of breast cancer, as well. MiR-
210 is differently expressed between TN and ER posi-
tive/HER2 negative breast cancers: higher expression is
in TN breast cancers than in ER positive/HER2 negative
breast cancers [28]. A non-significant tendency of high
expression level of miR-210 and other miRNAs (miR-21,
miR-221, and miR-222) is related to worse overall and
disease-free survival of TN breast cancer patients [29].
In another study, TN patients with high expression of
miR-210 showed considerably worse overall and disease-
free survival than those with low expression of miR-210
[28]. In contrast, breast cancer patients with negative ex-
pression of miR-34b have worse overall and disease-free
survival compared to those with positive expression of
miR-34b [30].
The aim of this study was to look for the miRNA that
differs in expression between TN hereditary and sporadictumors and associate expression level of some miRNA to
disease specific survival of TN breast cancer patients.
Material and methods
Eighteen TN breast cancer patients harboring the BRCA1
gene mutations and 32 triple-negative sporadic breast
cancer patients hospitalized at Pauls Stradins Clinical
University Hospital and/or Latvian Oncology Center from
2004 to 2011 were involved in this study. All patients
signed informed consent forms.
The BRCA1 gene mutations (5382insC, 4153delA, and
C61G) were determined by multiplex polymerase chain
reaction [31]. Breast cancer patients with the BRCA1
gene mutations were defined as hereditary [31].
TN tumors were defined as ER and PR 0% and HER2
protein 0%. This study included only those TN tumor
tissues which tumor cell content per specimen was more
than 50%. All histological data was reviewed and evalu-
ated by pathologist. Immunohistochemistry data was
analyzed and interpreted by pathologist.
MiRNAs were isolated from the formalin-fixed and
paraffin embedded tumor tissues with the RecoverAll
Total Nucleic Acid Isolation Kit (Ambion, Applied
Biosystems). Reaction of the reverse transcription was
done with the TaqMan MicroRNA Reverse Transcription
Kit (Applied Biosystems) on the TProfessional Thermal
Cycler (Biometra). Quantitative analysis of miRNAs was
performed with real-time PCR (Rotor-Gene 6000, Corbett)
using TaqMan MicroRNA Assays (Applied Biosystems).
Each sample was performed in three repeats. The expres-
sion levels were analyzed with the Rotor-Gene Q Series
Software 1.7 using comparative quantitation analysis. Each
miRNA was normalized by the internal reference RNU6B.
The disease-specific survival was evaluated from the
date of the diagnosis till the date of the death from the
malignancy. The disease-specific survival was analyzed
using the Log-rank (Mantel-Cox) test. The level of the
statistical significance was set at the 95%. The median
follow-up period of the TN breast cancer patients was
40 months. According to the American Joint Committee
on Cancer (AJCC), as a T1/T2 group were defined
tumors that were ≤ 20 mm to ≤ 50 mm in dimension.
T3/T4 group were defined tumors that were >50 mm in
dimension to any size with direct extension to the chest
wall and/or to the skin [AJCC]. Whitney–Mann test was
used to calculate miRNA expression differences between
TN-H and TN-S tumor tissues. Clinical and pathological
characteristics between the BRCA1 gene mutation carriers
and non-carriers were compared by t-test and Fisher’s
exact test.
Results
TN breast cancer patients with the BRCA1 gene muta-
tions at the time of the diagnosis were younger than
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TN patients with staging T3 were in sporadic group than
in hereditary one (p = 0.0731). Between hereditary breast
cancer patients stage I was more frequent than between
sporadic ones (p = 0.0889). Medullary carcinomas were
significantly more in hereditary group comparing to
sporadic one (p = 0.0442) (Table 1).
Association between the median ± standard deviation
expression of each miRNA and T stages (T1/2 and T3/4)
was explored. Statistically not quite a significant differenceTable 1 Clinical and pathological characteristics of BRCA1










Age at diagnosis, years
Median 46 55 0.0648
Range 27-72 28-78
T stage
T1 7 (38.89) 6 (18.75) 0.1797
T2 7 (38.89) 15 (46.88) 0.7676
T3 1 (5.56) 9 (28.13) 0.0731
T4 3 (16.67) 2 (6.25) 0.3363
Nodal status
N0 12 (66.67) 19 (59.38) 0.7637
N1 0 (0.00) 4 (12.50) 0.2828
N2 5 (27.28) 6 (18.75) 0.4944
N3 1 (5.56) 3 (9.38) 0.9999
Metastasis
M0 17 (94.44) 31 (96.88) 0.9999
M1 1 (5.56) 1 (3.13) 0.9999
Stage
I 7 (38.89) 5 (15.63) 0.0889
II 5 (27.78) 14 (43.75) 0.3659
III 5 (27.78) 12 (37.50) 0.5482
IV 1 (5.56) 1 (3.13) 0.9999
Histology
Ductal carcinoma 14 (77.78) 28 (87.50) 0.3984
Tubular carcinoma 0 (0.00) 1 (3.13) 0.9999
Medullary carcinoma 3 (16.67) 0 (0.00) 0.0442
Papillary carcinoma 1 (5.56) 2 (6.25) 0.9999
No data 0 (0.00) 1 (3.13)
Tumor grade
Moderately differentiated 3 (16.67) 1 (3.13) 0.1142
Poorly differentiated 12 (66.67) 27 (84.38) 0.1142
No data 3 (16.67) 4 (12.50)
Ki-67 73 70 0.6494between T1/2 and T3/4 groups in the case of miR-31 was
observed (p = 0.0666) (Table 2).
The expression level of miR-10b, miR-21, miR-29a,
miR-31, and miR-214 in 18 TN-H and 32 TN-S breast
tumors was analyzed. Measurements were normalized to
internal control RNU6B. After normalization outliers
were excluded. The median expression level ± inter-
quartile range (Q1; Q3) of miR-10b, miR-21, miR-29a,
miR-31, and miR-214 in TN-H cancer tissues was 0.275 ±
0.287 (0.122; 0.408), 5.725 ± 4.250 (2.408; 6.658), 1.330 ±
1.552 (0.478; 2.030), 0.254 ± 0.642 (0.041; 0.684), and
0.489 ± 1.027 (0.350; 1.378), respectively. The median ex-
pression level ± interquartile range (Q1; Q3) of miR-10b,
miR-21, miR-29a, miR-31, and miR-214 in TN-S breast
cancer tissues was 0.330 ± 0.381 (0.249; 0.631), 9.580 ±
7.545 (5.405; 12.950), 1.490 ± 0.990 (1.180; 2.170), 0.592 ±
0.487 (0.332; 0.819), and 1.800 ± 1.250 (1.170; 2.420),
respectively. MiR-214 showed significantly higher ex-
pression level in TN-S tumor tissues than in TN-H ones
(Figure 1).
Disease-specific survival of the TN breast cancer pa-
tients in respect of high and low levels of miR-10b, miR-
21, miR-31, and miR-214 was analyzed. High and low
expression levels were defined as values above and below
median expression level, respectively. The median expres-
sion ± interquartile range (Q1; Q3) of miR-10b, miR-21,
miR-31, and miR-214 was 0.327 ± 0.337 (0.198; 0.535),
6.990 ± 9.245 (3.105; 12.350), 0.488 ± 0.599 (0.214; 0.813),
and 1.455 ± 1.593 (0.625; 2.218), respectively. TN breast
cancer patients with high expression level of miR-214
showed significantly worse disease-free survival than
patients with low expression of this miRNA (Figure 2).
Discussion
In this study, the BRCA1 gene mutation carriers at the
time of the diagnosis were younger than patients with
no evadable changes in the BRCA1 gene. Finding is con-
sistent with other studies; the BRCA1 gene mutation
carriers at the time of the diagnosis were younger than
sporadic breast cancer patients [8]. Medullary carcin-
omas were seen more in BRCA1 carriers than non-
carriers. There has been observed a weak correlation
between BRCA1 mutation status and medullar histology
of breast cancer [32,33].Table 2 Association between expression level of each
miRNA and T stage
miRNA T1/2±SD T3/4±SD P-value
miR-10b 0.289 ± 0.288 0.421 ± 0.210 0.1411
miR-21 6.180 ± 5.736 7.910 ± 4.554 0.3093
miR-29a 1.475 ± 1.089 1.825 ± 0.983 0.3399
miR-31 0.299 ± 0.493 0.592 ± 0.472 0.0666
miR-214 1.230 ± 1.95 1.700 ± 0.856 0.3775
Figure 1 Different miRNA expression between TN-H and TN-S breast cancer tissues. Statistical significance was set at the 95% level.
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higher expression level of miR-214 than TN hereditary
individuals that are consistent with the finding in other
study; miR-214 is expressed differentially in ovary cancer
patients with and without the BRCA1 gene mutations
[26]. High grade serous carcinoma patients with any loss
within the BRCA1 gene show lower expression of miR-
214 than patients with no change [26]. The disease-
specific survival in respect of high and low expression
level of miR-214 was analyzed. TN breast cancer pa-
tients with high expression level of miR-214 have signifi-
cantly worse disease-specific survival than patients with
low expression of miR-214. According to the results of
this study, in the breast cancer, miR-214 may act
similarly as oncogene that is consistent with the finding
in other study. MiR-214 is up-regulated in preoperative
serum samples of breast cancer patients; whereas, in
post-operative serum samples, it is decreased and in-
creased miR-214 correlates with positive lymph node
status [34]. MiR-214 plays an important role not only inthe ovary cancer but as well in the breast cancer devel-
opment. It is not clear how BRCA1 dysfunction can
influence the level of miR-214 in ovarian and breast tu-
mors as yet. It is known that miR-214 targets the PTEN
gene; by targeting PTEN Akt pathway is activated thus
resulting in the cell survival [35]. In many different types
of cancers, in about 40% of ovarian and breast cancers,
Akt kinase activity has been detected increased [36].
In advanced (metastatic) breast cancers, expression of
miR-10b is up-regulated as compared to the primary
ones [36]. MiR-10b is directly involved in the suppres-
sion of the HOXD10 that in turn activates expression of
the pro-metastatic gene RHOC [36]. MiR-10b correlation
between tumor size, histological grade, clinical stage,
positive lymph node status, and HER2 expression is
positive [37]. While the correlation between high expres-
sion of miR-10b and HER2 expression is positive; the
correlation between miR-10b expression and PR and ER
status is negative [37]. Over-expression of miR-10b* is
associated with reduced disease-free, relapse-free, and
Figure 2 Disease-specific survivals of TN breast cancer patients in regard of high and low expression of miRNAs. Statistical significance
was set at the 95% level.
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expression level [38]. TN-S breast cancer tissues have
higher expression level of miR-10b than TN-H ones,
though the difference is not quite statistically significant.
In addition, the frequency of T3 is higher in sporadic
group than in hereditary one. The TN hereditary breast
cancer patients at the time of diagnosis have smaller
tumor size than sporadic ones [7-9]. A non-significant
higher frequency of T3 in sporadic group suggests that
sporadic breast cancer patients have higher frequency of
tumors that are greater than 5 cm across than hereditary
ones. Moreover, the frequency of stage I among heredi-
tary breast cancer patients is higher than between spor-
adic breast cancer patients. Findings in this study support
findings in other studies.
Another miRNA that in this study was up-regulated in
TN-S tissues as compared to TN-H ones was miR-21.
As well as in this case, difference between groups was
not quite statistically significant. MiR-21 is up-regulated
in TN primary breast cancers as compared to healthy
breast tissues [29]. Expression of miR-21 is significantly
higher in ERα positive, ErbB2 negative, and PR positive
than in ERα negative, ErbB2 positive, and PR negativebreast cancers [16]. MiR-21 is regulated by both ER
(ERα and ERβ) receptors. Interaction between estradiol
(E2) and one of the two ER receptors leads to the inhib-
ition of miR-21 expression thus resulting in a loss of
suppression of PDCD4, PTEN and BCL2 protein expres-
sion [39]. In addition, interaction between E2 and ERα dir-
ectly increases transcription of BCL2 [39]. The mRNA
profiling analysis revealed that in the adjacent normal
breast tissues compared to TN ones, oncogenic BCL2 is
down-regulated whereas miR-21 in TN breast cancer tis-
sues is over-expressed [40]. Breast cancer patients with ER
negative and PR negative receptor status have significantly
higher expression of miR-21 than breast cancer patients
with ER positive and PR positive receptor status [24]. TN
breast cancer patients with high expression level of miR-
21 have a non-significant tendency of worse overall and
disease-free survival than to those with low expression of
miR-21 [29].
In this study higher expression level of miR-31 was in
TN-S tumor tissues than in TN-H ones; however, as well
in this case the difference was not quite statistically sig-
nificant. Up-regulation of miR-31 is associated with less
aggressive breast cancer subtypes, like luminal ones;
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sive breast cancer subtypes, like triple-negative ones. In
the MDA-MB-231 (triple-negative breast cancer sub-
type) cell lines miR-31 is found down-regulated whereas
in the MCF7 (luminal breast cancer subtype) cell lines
up-regulated [41,42].
Conclusions
According to the results of this study miR-214 is an indi-
cator for the TN breast cancer patient’s poor prognosis
and possibly could be used as a potential prognostic bio-
marker for TN breast cancer subtype.
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